Why healthcare costs are New York’s true affordability emergency

Listen to this article

Upstate New Yorkers understand the word “affordability.” We routinely debate the soaring cost of housing, utility bills, and property taxes. Yet, in these crucial conversations, the single largest threat to household budgets and small business viability, the cost of healthcare, often gets relegated to the back burner. This silence is deafening, as the escalation of health insurance prices, driven by the relentless escalating cost of specialty drugs, mandates, and unchecked hospital prices, is creating an environment that is proving extremely difficult for local businesses and individuals to thrive and survive.

One of the most volatile drivers of today’s premium increases is the pharmaceutical sector. The rapid adoption and sky-high prices of specialty medications, particularly the new GLP-1 agonists (for diabetes and weight management) and complex biologic drugs, are adding unprecedented strain to insurance plans across the state. Unknown to many people, these treatments often carry five- and six-figure annual price tags per patient. The widespread utilization of GLP-1s, for instance, means the collective cost burden for employers is growing exponentially, regardless of whether employees ever step foot in a hospital. New York businesses are forced to absorb these pharmacy expenses, squeezing margins and limiting hiring.

Compounding the pharmaceutical crisis is the market dominance of New York’s largest hospital systems. These growing entities have amassed hundreds of millions in financial reserves, built in large part on market leverage. Through aggressive negotiations, they extract exorbitant rates from private insurers and their premium-payers. The choice becomes clear: either pay the price set by the health system or leave the network, a “choice” that often isn’t really a choice at all for many plans and many patients.

Healthcare affordability must be elevated to the highest level of priority in Albany. We need a holistic approach that tackles both the price of pharmaceuticals and the consolidation of facilities. This means curbing pharmaceutical inflation by demanding price transparency and mechanisms to curb the runaway costs of highly utilized specialty medications. It also means applying serious scrutiny to hospital-physician mergers and limiting the disparity in payment rates between consolidated systems and independent providers.

Until New York confronts the actions of its dominant healthcare players and the unsustainable cost of modern drugs, our state will continue to be a place where financial stability is undermined by runaway healthcare costs. It’s time to demand affordability in the one sector that most determines our well-being.

Justin Wilcox is executive director of Upstate United, a nonpartisan business and taxpayer advocacy coalition focused on growing the upstate economy.